{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:15:12Z","timestamp":1779207312601,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.diabet.2026.101760","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:33:02Z","timestamp":1776011582000},"page":"101760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative cardiovascular effectiveness of GLP-1RAs versus DPP-4is in dialysis patients with type 2 diabetes: a target trial emulation"],"prefix":"10.1016","volume":"52","author":[{"given":"Hiroki","family":"Shimada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0737","authenticated-orcid":false,"given":"Toshiki","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Okazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasumi","family":"Yokogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2026.101760_bib0002","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ijcard.2015.09.119","article-title":"Cardiac event risk stratification in patients with end-stage renal disease: sub-analysis of the B-SAFE study","volume":"202","author":"Zen","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2026.101760_bib0003","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2026.101760_bib0004","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2026.101760_bib0005","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101760_bib0006","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101760_bib0007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/diseases12010014","article-title":"Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis","volume":"12","author":"Krisanapan","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.diabet.2026.101760_bib0008","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2026.101760_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2026.101760_bib0010","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2215\/CJN.0000000750","article-title":"GLP-1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis","volume":"20","author":"Orandi","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2026.101760_bib0011","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial-the TARGET statement","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2026.101760_bib0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.37737\/ace.25006","article-title":"DeSC database","volume":"7","author":"Yasunaga","year":"2025","journal-title":"Ann Clin Epidemiol"},{"key":"10.1016\/j.diabet.2026.101760_bib0013","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/ANNALS-24-03237","article-title":"Cardiovascular safety and fracture prevention effectiveness of denosumab versus oral bisphosphonates in patients receiving dialysis: a target trial emulation","volume":"178","author":"Masuda","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2026.101760_bib0014","first-page":"190","article-title":"Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people","volume":"5","author":"Okada","year":"2022","journal-title":"JMA J"},{"key":"10.1016\/j.diabet.2026.101760_bib0015","doi-asserted-by":"crossref","DOI":"10.37737\/ace.27004","article-title":"From insurance records to epidemiology: provenance and processing of Japanese claims data","author":"Nakao","year":"2026","journal-title":"Ann Clin Epidemiol"},{"key":"10.1016\/j.diabet.2026.101760_bib0016","doi-asserted-by":"crossref","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","article-title":"The target trial framework for causal inference from observational data: why and when is it helpful?","volume":"178","author":"Hern\u00e1n","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2026.101760_bib0017","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/M18-3079","article-title":"Graphical depiction of longitudinal study designs in health care databases","volume":"170","author":"Schneeweiss","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2026.101760_bib0018","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.2337\/dc23-0671","article-title":"Comparative cardiovascular effectiveness and safety of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors according to frailty in type 2 diabetes","volume":"46","author":"Kutz","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101760_bib0019","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-024-02150-0","article-title":"Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study","volume":"23","author":"Htoo","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2026.101760_bib0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/endrev\/bnab007","article-title":"Conducting real-world evidence studies on the clinical outcomes of diabetes treatments","volume":"42","author":"Schneeweiss","year":"2021","journal-title":"Endocr Rev"},{"key":"10.1016\/j.diabet.2026.101760_bib0021","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/10870547231214993","article-title":"Cardiovascular safety of atomoxetine and methylphenidate in patients with attention-deficit\/hyperactivity disorder in japan: a self-controlled case series study","volume":"28","author":"Zheng","year":"2024","journal-title":"J Atten Disord"},{"key":"10.1016\/j.diabet.2026.101760_bib0022","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1253\/circj.CJ-25-0002","article-title":"JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure","volume":"89","author":"Kitai","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.diabet.2026.101760_bib0023","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/pds.5213","article-title":"Accuracy of Japanese claims data in identifying diabetes-related complications","volume":"30","author":"Fujihara","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabet.2026.101760_bib0024","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/sim.8471","article-title":"A causal framework for classical statistical estimands in failure-time settings with competing events","volume":"39","author":"Young","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.diabet.2026.101760_bib0025","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-159-8-201310150-00709","article-title":"Randomized trials analyzed as observational studies","volume":"159","author":"Hern\u00e1n","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2026.101760_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70063","article-title":"Impact of early resumption of oral anticoagulation on recurrence after surgery for chronic subdural hematoma in patients with atrial fibrillation: a target trial emulation","volume":"33","author":"Anno","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabet.2026.101760_bib0027","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2026.101760_bib0028","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.diabet.2026.101760_bib0029","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1740774511420743","article-title":"Beyond the intention-to-treat in comparative effectiveness research","volume":"9","author":"Hern\u00e1n","year":"2012","journal-title":"Clin Trials"},{"key":"10.1016\/j.diabet.2026.101760_bib0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabet.2026.101760_bib0031","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jdiacomp.2017.12.005","article-title":"Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring","volume":"32","author":"Yajima","year":"2018","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabet.2026.101760_bib0032","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41100-022-00409-4","article-title":"An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","volume":"8","author":"Ugamura","year":"2022","journal-title":"Ren Replace Ther"},{"key":"10.1016\/j.diabet.2026.101760_bib0033","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/dom.14600","volume":"24","author":"Hirose","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2026.101760_bib0034","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2026.101760_bib0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101760_bib0036","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101760_bib0037","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101760_bib0038","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","article-title":"Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality","volume":"18","author":"London","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabet.2026.101760_bib0039","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101760_bib0040","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2337\/dc15-1025","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial","volume":"39","author":"Idorn","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101760_bib0041","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0140-6736(13)61836-X","article-title":"Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1\u00b78 million participants","volume":"383","author":"Lu","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2026.101760_bib0042","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1681\/ASN.2013070754","article-title":"Association of body mass index with outcomes in patients with CKD","volume":"25","author":"Lu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2026.101760_bib0043","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101760_bib0044","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1681\/ASN.0000000000000321","article-title":"Daprodustat and heart failure in CKD","volume":"35","author":"Cunningham","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2026.101760_bib0045","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/ndt\/16.12.2386","article-title":"Body mass index and mortality in \u201chealthier\u201d as compared with \u201csicker\u201d haemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS)","volume":"16","author":"Leavey","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabet.2026.101760_bib0046","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1097\/01.ASN.0000100127.54107.57","article-title":"Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns study (DOPPS)","volume":"14","author":"Goodkin","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2026.101760_bib0047","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000441573","article-title":"Differences in the characteristics of dialysis patients in Japan compared with those in other countries","volume":"40","author":"Kimata","year":"2015","journal-title":"Blood Purif"},{"key":"10.1016\/j.diabet.2026.101760_bib0048","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.mayocp.2024.12.019","article-title":"Association between body mass index and age at end-stage renal disease in patients with autosomal dominant polycystic kidney disease in the United States and Japan","volume":"100","author":"Suwabe","year":"2025","journal-title":"Mayo Clin Proc"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236362600039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236362600039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:56:06Z","timestamp":1779206166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S126236362600039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S126236362600039X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101760","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative cardiovascular effectiveness of GLP-1RAs versus DPP-4is in dialysis patients with type 2 diabetes: a target trial emulation","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101760"}}